Logo

Danger signals and inflammaging in osteoarthritis

1, 2, 3

  1. Sorbonne University, INSERM (UMR S938) and Labex Transimmunom, Paris, France.
  2. Sorbonne University, INSERM (UMR S938) and Labex Transimmunom, Paris, and Department of Rheumatology, AP-HP, APHP-Sorbonne University, Paris, France. francis.berenbaum@aphp.fr
  3. Sorbonne University, INSERM (UMR S938) and Labex Transimmunom, Paris, France.

CER12605 Submission on line
2019 Vol.37, N°120 ,Suppl.120 - PI 0048, PF 0056
Pathophysiology

Free to view (click on article PDF icon to read the article)

Rheumatology Article

 

Abstract

Osteoarthritis (OA) is the most common age-related chronic and disabling joint disease. Long considered to be a “wear and tear” disease, OA is now seen as a low-grade inflammation disease that affects all tissues of the joint, involving cartilage degradation, bone remodelling, osteophytes, and synovitis. The process, called inflammaging, is characterised by the association of low-grade inflammation, profound changes in intra-cellular mechanisms, and the decreased efficiency of the immune system with ageing. The activation of innate immunity plays a critical role in the development and progression of OA. Innate immunity, including inflammasome activation, is triggered by small endogenous molecules called alarmins or damage-associated molecular patterns (DAMPs). These molecules are released in the extracellular media after cell stress or damage, bind to pathogen-recognition receptors (PRRs), such as Toll-like receptors (TLRs) and the receptor for advanced glycation end products (RAGE), and activate the secretion of pro-inflammatory factors, leading to joint inflammation. Moreover, such sterile inflammation triggers cell senescence, characterised by a senescence-associated secretory phenotype (SASP). Understanding the substantial age-related changes of joint tissues that influence the pathogenesis of OA is critical to improving the quality of life of elderly people in the context of increased life expectancy. This review will focus on age-related sterile inflammation in OA and highlight the various innovative and promising therapies targeting the mechanisms of aging.

PMID: 31621566 [PubMed]

Received: 18/07/2019 - Accepted : 04/09/2019 - In Press: 15/10/2019 - Published: 15/10/2019